A relative unknown, if you don't watch the biotherapeutics industry, Iovance Biotherapeutics ( NASDAQ:IOVA ) surged 43% in the past week after reporting Q4 2025 earnings on February 24, pushing Reddit sentiment to 86 out of 100. ...

Key Takeaways Iovance reported a Q4 loss of 18 cents per share on $87M in revenues, topping estimates.IOVA's Amtagvi sales rose 33% to $65M, lifting gross margin to 50% after restructuring.IOVA shares jumped 31% on 50% ORR data in sarcoma and a new study plan.Iovance Biotherapeutics (IOVA) incurred a fourth-quarter 2025 loss of 18 cents per share, narrower than the Zacks Consensus Estimate of a loss of 22 cents. In the year-ago quarter, the company reported a loss per share of 26 cents.Total revenues for th ...

US stock market today saw the 49,369.65 (+0.40%), the S&P 500 climb to 6,927.93 (+0.55%), and the 23,044.10 (+0.79%), as investors rotated back into technology and artificial intelligence stocks ahead of a critical earnings catalyst. The rally comes amid renewed optimism around AI spending, easing fears of software disruption, and fresh policy signals from President Donald Trump’s 2026 State of the Union address. The answer to what is driving the US stock market today is clear: Nvidia earnings expectations, ...

Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. This article is intended to provide informational content and should not be viewed as an exhaustive a ...

Iovance Biotherapeutics (NASDAQ:IOVA) shares are surging on Tuesday following the announcement of positive early data from a pilot clinical trial for its TIL cell therapy in advanced soft-tissue sarcomas.This news has energized investors as the broader market is experiencing gains, with the Nasdaq up 0.51%.Among the first six evaluable patients treated with lifileucel monotherapy, the trial showed a 50% confirmed objective response rate (ORR).The trial, conducted by Memorial Sloan Kettering Cancer Center, f ...

Key Takeaways Iovance's Amtagvi sales jumped 183% in the first nine months of 2025, driving growth.IOVA cut its 2025 revenue guidance and withdrew its EU filing for Amtagvi, hurting shares.Rigel's 2025 sales rose 60% to $232M, led by Tavalisse, with 2026 growth projected.Both Iovance Biotherapeutics (IOVA) and Rigel Pharmaceuticals (RIGL) are small-cap companies focused on the successful commercialization of their marketed products.While Iovance is a cancer biotech concentrated on developing immunotherapies ...

Product Development and Approvals - Amtagvi® has the potential to address over 30,000 previously treated advanced melanoma patients annually, with approvals in the U.S. and Canada, and pending approvals in the UK and Australia by 2026[538]. - The U.S. accelerated approval of Amtagvi® is based on safety and efficacy results from the C-144-01 global, multicenter clinical trial, with a Phase 3 confirmatory trial ongoing[544]. - The company is conducting two ongoing registrational trials in frontline advanced melanoma and previously treated advanced non-small cell lung cancer (NSCLC)[539]. - Iovance acquired worldwide rights to Proleukin® in May 2023, enhancing its commercial strategy and revenue channels[546]. - The company plans to resubmit a centralized marketing authorization application in the EU in 2026 after withdrawing its initial application in July 2025[538]. Financial Performance - Revenue for the year ended December 31, 2025, is primarily driven by product sales of Amtagvi® and Proleukin®, with Amtagvi® revenue recognized upon patient infusion and Proleukin® revenue upon shipment[558][559]. - Amtagvi® revenue for the year ended December 31, 2025, was $220.0 million, a 112% increase from $103.6 million in 2024[574]. - Total product revenue increased by $99.4 million, or 61%, to $263.5 million in 2025 compared to $164.1 million in 2024[574]. - Total product revenue for the year ended December 31, 2024 increased by $162.9 million, or 13,698%, compared to 2023, due to the acquisition of Proleukin® and the launch of Amtagvi®[592]. Costs and Expenses - Cost of sales increased by $79.9 million, or 86%, to $173.2 million in 2025, driven by higher sales of Amtagvi® and related manufacturing costs[576][577]. - Research and development expenses rose by $24.0 million, or 9%, to $300.3 million in 2025, primarily due to increased clinical trial costs and payroll[578][583]. - Selling, general, and administrative expenses remained flat at $152.3 million in 2025 compared to $152.3 million in 2024[584]. - Research and development expense for the year ended December 31, 2024 decreased by $57.0 million, or 17%, compared to 2023, primarily due to a decrease in clinical manufacturing costs[599]. - Selling, general, and administrative expense for the year ended December 31, 2024 increased by $46.2 million, or 44%, compared to 2023, mainly due to increased payroll and related expenses[603]. Cash Flow and Financing - As of December 31, 2025, the company had $303.0 million in cash, cash equivalents, short-term investments, and restricted cash, with $163.1 million in cash and cash equivalents[611]. - Net cash used in operating activities for the year ended December 31, 2025, was $302.4 million, a decrease from $353.0 million in 2024, driven by increased sales of Amtagvi®[620]. - Net cash provided by investing activities for the year ended December 31, 2025, was $47.5 million, a significant improvement from net cash used of $96.4 million in 2024[625]. - Net cash provided by financing activities for the year ended December 31, 2025, was $300.8 million, a decrease from $390.7 million in 2024, primarily due to lower net proceeds from common stock sales[628]. - During the year ended December 31, 2025, the company received $306.3 million in net proceeds from the sale of common stock[616]. Strategic Initiatives - A strategic restructuring plan was approved in August 2025, resulting in a workforce reduction of approximately 19% to optimize business performance and extend cash runway[613]. - The company anticipates continued increases in selling, general, and administrative expenses as it expands the use of Amtagvi® and Proleukin®[568]. - The company expects to continue incurring significant expenses to support commercial activities for Amtagvi® and ongoing clinical programs, indicating a focus on research and development[612]. Market and Operational Risks - The company anticipates that revenues from Amtagvi® and Proleukin® may not be sufficient to generate positive operational cash flows within the next 12 months[611]. - The company's operating results could be significantly affected by changes in foreign currency exchange rates, particularly with the pound sterling[660]. - Foreign currency transaction gains and losses were immaterial for the years ended December 31, 2025, and 2024, indicating no significant foreign currency exchange risk[661]. Research and Development Focus - Research and development activities are central to the business model, with a focus on late-stage clinical development candidates[581]. - The company expects to continue incurring research and development expenses for ongoing clinical trials and product candidates[566]. - The company recognizes accrued research and development costs as expenses incurred, with significant costs related to clinical trials[651]. Compliance and Regulatory Matters - The company reviews intangible assets for impairment at least annually, with no indicators of impairment noted as of December 31, 2025[644]. - Revenue recognition follows ASC 606, with revenue recognized when control of goods is transferred to customers[646]. - The company has no off-balance sheet arrangements as of December 31, 2025[633].

Iovance Biotherapeutics (NasdaqGM:IOVA) Q4 2025 Earnings call February 24, 2026 08:30 AM ET Company ParticipantsAndrew Tsai - Managing DirectorBrian Gastman - EVP of Transitional Medicine and ResearchCorleen Roche - CFODan Kirby - Chief Commercial OfficerDavid Dai - DirectorFrederick Vogt - Interim CEO and PresidentIgor Bilinsky - COOReni Benjamin - Managing DirectorSara Pellegrino - SVP of Investor Relations and Corporate CommunicationsNone - Company RepresentativeConference Call ParticipantsAsthika Goonew ...

Iovance Biotherapeutics (NasdaqGM:IOVA) Q4 2025 Earnings call February 24, 2026 08:30 AM ET Company ParticipantsAndrew Tsai - Managing DirectorBrian Gastman - EVP of Transitional Medicine and ResearchCorleen Roche - CFODan Kirby - Chief Commercial OfficerDavid Dai - DirectorFrederick Vogt - Interim CEO and PresidentFriedrich Finckenstein - Chief Medical OfficerIgor Bilinsky - COOReni Benjamin - Managing DirectorSara Pellegrino - SVP of Investor Relations and Corporate CommunicationsNone - Company Representa ...

Iovance Biotherapeutics (NasdaqGM:IOVA) Q4 2025 Earnings call February 24, 2026 08:30 AM ET Speaker9Good day. Thank you for standing by. Welcome to the Iovance Biotherapeutics fourth quarter and full year 2025 financial results and corporate updates conference call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question and answer session. To ask a question during this session, you will need to press star one one on your telephone. You will hear ...